TNFRSF1A抗体;TNFRSF1A Antibody—艾普蒂

+ +

•  

   

     :Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using TNFRSF1A mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of THP-1 cells using TNFRSF1A mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of Jurkat cells using TNFRSF1A mouse mAb (green) and negative control (red).    

  
  

TNFRSF1A (tumor necrosis factor receptor superfamily member 1A) is a transmembrane protein that binds tumor necrosis factor-alpha (TNF-α) and lymphotoxin-alpha, playing a central role in inflammation, apoptosis, and immune regulation. Structurally, it contains extracellular cysteine-rich domains for ligand binding, a transmembrane region, and an intracellular death domain for signaling. Dysregulation of TNFRSF1A is linked to autoimmune and autoinflammatory disorders, notably TNF receptor-associated periodic syndrome (TRAPS), a rare hereditary condition caused by germline mutations in the TNFRSF1A gene. These mutations often impair receptor shedding or disrupt normal signaling, leading to prolonged inflammation and symptoms like recurrent fever, rash, and systemic inflammation.

Antibodies targeting TNFRSF1A have dual roles in research and clinical contexts. In research, they serve as tools to study receptor-ligand interactions, downstream signaling pathways (e.g., NF-κB, apoptosis), and disease mechanisms. Clinically, anti-TNFRSF1A antibodies or engineered biologics (e.g., etanercept) may neutralize soluble TNF-α to treat autoimmune diseases like rheumatoid arthritis. However, autoantibodies against TNFRSF1A have also been detected in certain autoimmune conditions, where they potentially contribute to pathogenesis by blocking receptor function or promoting aberrant signaling. Understanding these antibodies aids in developing targeted therapies and diagnostic biomarkers for TNFRSF1A-related disorders.